Immunomedics Inc. (IMMU)

18.73
NASDAQ : Health Technology
Prev Close 19.10
Day Low/High 18.60 / 19.41
52 Wk Low/High 12.06 / 27.33
Avg Volume 1.93M
Exchange NASDAQ
Shares Outstanding 190.43M
Market Cap 3.71B
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BLFS, BOSC, HESM, PLAB, PSEC Downgrades: CREE, IMMU Initiations: FPH, RNGR Read on to get TheStreet Quant Ratings' detailed report:

3 Biotech Stock Favorites to Bet on Today: Top Analysts

3 Biotech Stock Favorites to Bet on Today: Top Analysts

Follow the experts. These biotech stocks have Wall Street's best analysts getting bullish.

The Charts of Immunomedics Look Very Bullish Now

The Charts of Immunomedics Look Very Bullish Now

Let's look at the charts and indicators to come up with a formula for success.

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EOCC, FET, IMMU, INVA, KMDA, SPH Downgrades: COR, EARN, EML, ENS, MSON, MYL, NCR, OFC, PBH, PCYO, THR, UBA, UBNT, UFS, WHG Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Revance Therapeutics Soars on Phase 3 Data -- Biotech Movers

Revance Therapeutics Soars on Phase 3 Data -- Biotech Movers

The Newark, Calif.-based firm unveiled positive top-line results from a pair of studies evaluating RT002 for the treatment of glabellar, or frown, lines.

Interesting IMMU Put And Call Options For December 15th

Interesting IMMU Put And Call Options For December 15th

Investors in Immunomedics, Inc. saw new options become available this week, for the December 15th expiration.

Short Interest Declines 14% For IMMU

Short Interest Declines 14% For IMMU

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 4,840,764 share decrease in total short interest for Immunomedics, Inc. , to 29,775,931, a decrease of 13.98% since 09/15/2017.

Kite Takeover by Gilead Lifts Biotech Stocks

Kite Takeover by Gilead Lifts Biotech Stocks

The key to dealing with this environment is to keep an open mind.

Immunomedics Announces Publication Of Phase 2 Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate Promising Efficacy As A Single Agent In Patients With Metastatic Colorectal Cancer

Immunomedics Announces Publication Of Phase 2 Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate Promising Efficacy As A Single Agent In Patients With Metastatic Colorectal Cancer

Results Appeared in Advanced Online Publication of the American Society of Clinical Oncology Journal, Journal of Clinical Oncology

TheStreet Quant Rating: D+ (Sell)